Work

Acetaminophen protein adduct concentrations during therapeutic dosing in patients with class II-III obesity compared to non-obese and overweight patients: a prospective observational gender stratified cohort study

Year: 2024

Type: article

Abstract: Background: Obese patients may need higher doses of acetaminophen (APAP) for adequate analgesia, due to increased total clearance and distribution volume. APAP-induced hepatotoxicity is mainly caused through CYP2E1 pathway. Its activity is induced by obesity, potentially endangering the safety profile of APAP. Metabolic-dysfunction associated liver disease (MASLD) is an important associated risk factor for APAP induced-hepatotoxicity. Objectives: This pilot study aimed at observing and analyzing CYP2E1 related protein adducts (APAP-cysteine and APAP-mercapturate) in obese compared to non-obese patients during therapeutic dosing of APAP. Study design and setting: Interim analysis of an ongoing prospective observational gender-stratified cohort PK study, conducted at Ghent University Hospital. Methods: 35 obese (BMI>35kg/m²) and 18 non-obese (18,5kg/m²

Source: Acta Anaesthesiologica Belgica

DOI: 10.56126/76.s1.16

Authors: H.A. De Baerdemaeker, P De Cock, L De Baerdemaeker

Institutions: Ghent University Hospital, Ghent University

Language: English

Topic: Drug-Induced Hepatotoxicity and Protection

Subfield: Pharmacology

Field: Pharmacology, Toxicology and Pharmaceutics

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4407637313